{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:58:47Z","timestamp":1791921527550,"version":"4.3.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Women's Health"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ibrexafungerp is a novel antifungal treatment for acute vulvovaginal candidiasis (VVC). Using pooled data from two phase three studies (VANISH 303 and 306) in the treatment of acute VVC, this analysis sought to determine the effectiveness of ibrexafungerp in various patient subgroups that may impact outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Data from VANISH 303 (NCT03734991) and VANISH 306 (NCT03987620) evaluating ibrexafungerp 300\u2009mg twice daily (BID) for 1 day versus placebo, were pooled and analyzed to determine clinical cure rate, clinical improvement, and mycological cure at the test-of-cure visit (day 11\u2009\u00b1\u20093) and symptom resolution at the follow-up visit (day 25\u2009\u00b1\u20094) in the overall population. Patient subgroups analyzed included race, body mass index (BMI), baseline vulvovaginal signs and symptoms (VSS) score, and\n                      <jats:italic toggle=\"yes\">Candida<\/jats:italic>\n                      species.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At the test-of-cure visit, patients receiving ibrexafungerp, compared with those who received placebo, had significantly higher rates of clinical cure (56.9% [214\/376 patients] vs. 35.7% [65\/182 patients]), clinical improvement (68.4% [257\/376 patients] vs. 45.1% [82\/182 patients]), and mycological cure (54.0% [203\/376 patients] vs. 24.2% [44\/182 patients]; all\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). At the follow-up visit, patients receiving ibrexafungerp had sustained responses with higher symptom resolution rates (66.8% [251\/376 patients]) versus placebo (48.4% [88\/182 patients];\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Race, BMI, baseline VSS score (including VSS severity score 13\u201318), and\n                      <jats:italic toggle=\"yes\">Candida<\/jats:italic>\n                      species infection did not adversely affect clinical cure rates. Safety analysis results were consistent with the individual studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Ibrexafungerp provides a safe and well-tolerated first-in-class fungicidal, 1-day oral treatment for patients with acute VVC, the first new therapy in &gt;20 years. Clinical Trial Registration Number: NCT03734991.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jwh.2022.0132","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T11:16:29Z","timestamp":1666091789000},"page":"178-186","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":25,"title":["Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306"],"prefix":"10.1177","volume":"32","author":[{"given":"Oluwatosin","family":"Goje","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, Case Western Reserve University, Cleveland, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Sobel","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Jefferson Vulvovaginal Health Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nyirjesy","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Jefferson Vulvovaginal Health Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, NYU Grossman School of Medicine, New York, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Spitzer","sequence":"additional","affiliation":[{"name":"Center for Colposcopy, New Hyde Park, New York, USA."},{"name":"Department of Obstetrics and Gynecology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Manhasset, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Faught","sequence":"additional","affiliation":[{"name":"Women's Institute for Sexual Health, Division of Urology Associates, PC, Nashville, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelagh","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Women and Infants, Acclaim Physician Group-Fort Worth, Fort Worth, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"King","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, SCYNEXIS, Inc., Jersey City, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nkechi E.","family":"Azie","sequence":"additional","affiliation":[{"name":"Department of Clinical Development and Medical Affairs, Wayne State University, Detroit, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Angulo","sequence":"additional","affiliation":[{"name":"Department of Research and Development, SCYNEXIS, Inc., Jersey City, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack D.","family":"Sobel","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Department of Internal Medicine, Wayne State University, Detroit, Michigan, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-169"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1701-2163(15)30316-9"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/jof4040121"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003857"},{"issue":"03","key":"e_1_3_6_6_2","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Workowski KA","year":"2015","unstructured":"Workowski KA, , Bolan GA, , Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep, 2015; 64(RR-03):1\u2013137.","journal-title":"MMWR Recomm Rep"},{"key":"e_1_3_6_7_2","first-page":"0815","article-title":"Candidiasis (vulvovaginal)","volume":"2015","author":"Martin Lopez JE","year":"2015","unstructured":"Martin Lopez JE. Candidiasis (vulvovaginal). BMJ Clin Evid, 2015; 2015:0815.","journal-title":"BMJ Clin Evid"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30103-8"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy776"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2018-0465"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1791820"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01961-16"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02611-18"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02119-18"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00562-21"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab750"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16972"},{"key":"e_1_3_6_18_2","unstructured":"Vulvovaginal candidiasis: Developing drugs for treatment. Guidance for Industry. Silver Spring (MD): Department of Health and Human Services (US) Food and Drug Administration; 2019 August [cited December 06 2021]. Available from: https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM509411.pdf [Last accessed: September 29 2022]."},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12485"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myv017"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0028-2243(88)90071-8"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2011.05.006"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab841"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(95)91490-0"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2001.115116"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200004000-00009"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199603000-00013"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.4236\/aid.2013.34035"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.15570\/actaapa.2015.2"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.01.021"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2015.1091805"}],"container-title":["Journal of Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jwh.2022.0132","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2022.0132","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jwh.2022.0132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:57:09Z","timestamp":1777658229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jwh.2022.0132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1089\/jwh.2022.0132"],"URL":"https:\/\/doi.org\/10.1089\/jwh.2022.0132","relation":{},"ISSN":["1540-9996","1931-843X"],"issn-type":[{"value":"1540-9996","type":"print"},{"value":"1931-843X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}